Effect of Biologic Therapies on Airway Hyperresponsiveness and Allergic Response: A Systematic Literature Review

References

• Coates AL, Wanger J, Cockcroft DW, et al. ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests. Eur Respir J. 2017;49(5):1601526. doi:10.1183/13993003.01526-2016
   PubMed Web of Science ®Google Scholar
• Hallstrand TS, Leuppi JD, Joos G, et al. ERS technical standard on bronchial challenge testing: pathophysiology and methodology of indirect airway challenge testing. Eur Respir J. 2018;52(5):1801033. doi:10.1183/13993003.01033-2018
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, El-Gammal AI, O’Byrne PM. Allergen-induced airway responses. Eur Respir J. 2015;46(3):819–831. doi:10.1183/13993003.00536-2015
   PubMed Web of Science ®Google Scholar
• Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med. 1999;159(4):1043–1051. doi:10.1164/ajrccm.159.4.9806052
   PubMed Web of Science ®Google Scholar
• Lauzon AM, Martin JG. Airway hyperresponsiveness; smooth muscle as the principal actor. F1000Res. 2016;5:306. doi:10.12688/f1000research.7422.1
   Google Scholar
• Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med. 2002;346(22):1699–1705. doi:10.1056/NEJMoa012705
   PubMed Web of Science ®Google Scholar
• Siddiqui S, Mistry V, Doe C, et al. Airway hyperresponsiveness is dissociated from airway wall structural remodeling. J Allergy Clin Immunol. 2008;122(2):335–341. doi:10.1016/j.jaci.2008.05.020
   PubMed Web of Science ®Google Scholar
• Corry DB, Folkesson HG, Warnock ML, et al. Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity. J Exp Med. 1996;183(1):109–117. doi:10.1084/jem.183.1.109
   PubMed Web of Science ®Google Scholar
• Wills-Karp M, Rani R, Dienger K, et al. Trefoil factor 2 rapidly induces interleukin 33 to promote type 2 immunity during allergic asthma and hookworm infection. J Exp Med. 2012;209(3):607–622. doi:10.1084/jem.20110079
   PubMed Web of Science ®Google Scholar
• Yang G, Volk A, Petley T, et al. Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling. Cytokine. 2004;28(6):224–232. doi:10.1016/j.cyto.2004.08.007
   PubMed Web of Science ®Google Scholar
• Altman MC, Lai Y, Nolin JD, et al. Airway epithelium-shifted mast cell infiltration regulates asthmatic inflammation via IL-33 signaling. J Clin Invest. 2019;129(11):4979–4991. doi:10.1172/JCI126402
   PubMed Web of Science ®Google Scholar
• Lai Y, Altemeier WA, Vandree J, et al. Increased density of intraepithelial mast cells in patients with exercise-induced bronchoconstriction regulated through epithelially derived thymic stromal lymphopoietin and IL-33. J Allergy Clin Immunol. 2014;133(5):1448–1455. doi:10.1016/j.jaci.2013.08.052
   PubMed Web of Science ®Google Scholar
• Al-Shaikhly T, Murphy RC, Parker A, et al. Location of eosinophils in the airway wall is critical for specific features of airway hyperresponsiveness and T2 inflammation in asthma. Eur Respir J. 2022;60:2101865. doi:10.1183/13993003.01865-2021
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777–792. doi:10.1080/14728222.2020.1783242
   PubMed Web of Science ®Google Scholar
• Calzetta L, Aiello M, Frizzelli A, et al. The impact of monoclonal antibodies on airway smooth muscle contractility in asthma: a systematic review. Biomedicines. 2021;9(9):1281. doi:10.3390/biomedicines9091281
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898
   PubMed Web of Science ®Google Scholar
• Boulet LP, Chapman KR, Côté J, et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med. 1997;155(6):1835–1840. doi:10.1164/ajrccm.155.6.9196083
   PubMed Web of Science ®Google Scholar
• Fahy JV, Fleming HE, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med. 1997;155(6):1828–1834. doi:10.1164/ajrccm.155.6.9196082
   PubMed Web of Science ®Google Scholar
• Fahy JV, Cockcroft DW, Boulet LP, et al. Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. Am J Respir Crit Care Med. 1999;160(3):1023–1027. doi:10.1164/ajrccm.160.3.9810012
   PubMed Web of Science ®Google Scholar
• Noga O, Hanf G, Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol. 2003;131(1):46–52. doi:10.1159/000070434
   PubMed Web of Science ®Google Scholar
• Djukanović R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004;170(6):583–593. doi:10.1164/rccm.200312-1651OC
   PubMed Web of Science ®Google Scholar
• Prieto L, Gutiérrez V, Colás C, et al. Effect of omalizumab on adenosine 5’-monophosphate responsiveness in subjects with allergic asthma. Int Arch Allergy Immunol. 2006;139(2):122–131. doi:10.1159/000090387
   PubMed Web of Science ®Google Scholar
• Patel BM, Chiang DT, Clark JP, Romero FA, Casale TB. 1022 Effects of omalizumab (Xolair®) on airway hyperresponsiveness. J Allergy Clin Immunol. 2009;123(2):S263. doi:10.1016/j.jaci.2008.12.1020
   Web of Science ®Google Scholar
• van Rensen EL, Evertse CE, van Schadewijk WA, et al. Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment. Allergy. 2009;64(1):72–80. doi:10.1111/j.1398-9995.2008.01881.x
   PubMed Web of Science ®Google Scholar
• Zielen S, Lieb A, De La Motte S, et al. Omalizumab protects against allergen-induced bronchoconstriction in allergic (immunoglobulin E-mediated) asthma. Int Arch Allergy Immunol. 2013;160(1):102–110. doi:10.1159/000339243
   PubMed Web of Science ®Google Scholar
• Hendeles L, Khan YR, Shuster JJ, Chesrown SE, Abu-Hasan M. Omalizumab therapy for asthma patients with poor adherence to inhaled corticosteroid therapy. Ann Allergy Asthma Immunol. 2015;114(1):58–62. doi:10.1016/j.anai.2014.10.012
   PubMed Web of Science ®Google Scholar
• Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000;356(9248):2144–2148. doi:10.1016/S0140-6736(00)03496-6
   PubMed Web of Science ®Google Scholar
• Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003;167(2):199–204. doi:10.1164/rccm.200208-789OC
   PubMed Web of Science ®Google Scholar
• Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(10):973–984. doi:10.1056/NEJMoa0808991
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Sehmi R, FitzGerald J, et al. 500 The effect of benralizumab on allergen-induced responses in subjects with mild allergic asthma. J Allergy Clin Immunol. 2021;147(2):AB157. doi:10.1016/j.jaci.2020.12.563
   Web of Science ®Google Scholar
• Gauvreau GM, O’Byrne PM, Boulet LP, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014;370(22):2102–2110. doi:10.1056/NEJMoa1402895
   PubMed Web of Science ®Google Scholar
• Diver S, Khalfaoui L, Emson C, et al. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299–1312. doi:10.1016/S2213-2600(21)00226-5
   PubMed Web of Science ®Google Scholar
• Sverrild A, Hansen S, Hvidtfeldt M, et al. The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM). Eur Respir J. 2022;59(1):2101296. doi:10.1183/13993003.01296-2021
   PubMed Web of Science ®Google Scholar
• Scheerens H, Arron JR, Zheng Y, et al. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge. Clin Exp Allergy. 2014;44(1):38–46. doi:10.1111/cea.12220
   PubMed Web of Science ®Google Scholar
• Russell RJ, Chachi L, FitzGerald JM, et al. Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial. Lancet Respir Med. 2018;6(7):499–510. doi:10.1016/S2213-2600(18)30201-7
   PubMed Web of Science ®Google Scholar
• Revez JA, Bain LM, Watson RM, et al. Effects of interleukin-6 receptor blockade on allergen-induced airway responses in mild asthmatics. Clin Transl Immunology. 2019;8(6):e1044. doi:10.1002/cti2.1044
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Becker AB, Boulet LP, et al. The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma. J Allergy Clin Immunol. 2003;112(2):331–338. doi:10.1067/mai.2003.1689
   PubMed Web of Science ®Google Scholar
• Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med. 2006;354(7):697–708. doi:10.1056/NEJMoa050580
   PubMed Web of Science ®Google Scholar
• Rouhani FN, Meitin CA, Kaler M, Miskinis-Hilligoss D, Stylianou M, Levine SJ. Effect of tumor necrosis factor antagonism on allergen-mediated asthmatic airway inflammation. Respir Med. 2005;99(9):1175–1182. doi:10.1016/j.rmed.2005.02.031
   PubMed Web of Science ®Google Scholar
• Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet. 2007;370(9596):1422–1431. doi:10.1016/S0140-6736(07)61600-6
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Boulet LP, Cockcroft DW, et al. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med. 2011;183(8):1007–1014. doi:10.1164/rccm.201008-1210OC
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Boulet LP, Cockcroft DW, et al. Effect of an anti-M1 prime monoclonal antibody, MEMP1972A, in a phase II proof-of-activity allergen challenge study in patients with mild asthma. Am J Respir Crit Care Med. 2012;185:A6793.
   Google Scholar
• Gauvreau GM, Hohlfeld JM, Grant S, et al. Efficacy and safety of an inhaled anti-TSLP antibody fragment in adults with mild atopic asthma. Am J Respir Crit Care Med. 2020;201:A4207.
   Web of Science ®Google Scholar
• Henig NR, Aitken ML, Liu MC, Yu AS, Henderson WR Jr. Effect of recombinant human platelet-activating factor-acetylhydrolase on allergen-induced asthmatic responses. Am J Respir Crit Care Med. 2000;162(2 Pt 1):523–527. doi:10.1164/ajrccm.162.2.9911084
   PubMed Web of Science ®Google Scholar
• Bryan SA, O’Connor BJ, Matti S, et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000;356(9248):2149–2153. doi:10.1016/S0140-6736(00)03497-8
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Boulet LP, Cockcroft DW, et al. OX40L blockade and allergen-induced airway responses in subjects with mild asthma. Clin Exp Allergy. 2014;44(1):29–37. doi:10.1111/cea.12235
   PubMed Web of Science ®Google Scholar
• Tajiri T, Niimi A, Matsumoto H, et al. Comprehensive efficacy of omalizumab for severe refractory asthma: a time-series observational study. Ann Allergy Asthma Immunol. 2014;113(4):470–475 e472. doi:10.1016/j.anai.2014.06.004
   PubMed Web of Science ®Google Scholar
• Chan R, RuiWen Kuo C, Jabbal S, Lipworth BJ. Eosinophil depletion with benralizumab is associated with attenuated mannitol airway hyperresponsiveness in severe uncontrolled eosinophilic asthma. J Allergy Clin Immunol. 2023;151(3):700–705. doi:10.1016/j.jaci.2022.10.028
   PubMed Web of Science ®Google Scholar
• Cahill KN, Katz HR, Cui J, et al. KIT inhibition by imatinib in patients with severe refractory asthma. N Engl J Med. 2017;376(20):1911–1920. doi:10.1056/NEJMoa1613125
   PubMed Web of Science ®Google Scholar
• Murphy RC, Chow YH, Lai Y, et al. Identification of mast cell progenitor cells in the airways of individuals with allergic asthma. Allergy. 2022;78:547–549. doi:10.1111/all.15498
   PubMed Web of Science ®Google Scholar
• Nakae S, Ho LH, Yu M, et al. Mast cell-derived TNF contributes to airway hyperreactivity, inflammation, and TH2 cytokine production in an asthma model in mice. J Allergy Clin Immunol. 2007;120(1):48–55. doi:10.1016/j.jaci.2007.02.046
   PubMed Web of Science ®Google Scholar
• Reuter S, Heinz A, Sieren M, et al. Mast cell-derived tumour necrosis factor is essential for allergic airway disease. Eur Respir J. 2008;31(4):773–782. doi:10.1183/09031936.00058907
   PubMed Web of Science ®Google Scholar
• Sze E, Bhalla A, Nair P. Mechanisms and therapeutic strategies for non-T2 asthma. Allergy. 2020;75(2):311–325. doi:10.1111/all.13985
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Corren J, Bourdin A, et al. Efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma: results from the phase 3 NAVIGATOR study (Abstract L46). J Allergy Clin Immunol. 2021;147(2):AB249.
   Web of Science ®Google Scholar
• Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800–1809. doi:10.1056/NEJMoa2034975
   PubMed Web of Science ®Google Scholar
• Panettieri RA Jr, Sjöbring U, Péterffy A, et al. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. Lancet Respir Med. 2018;6(7):511–525. doi:10.1016/S2213-2600(18)30184-X
   PubMed Web of Science ®Google Scholar
• Hanania NA, Korenblat P, Chapman KR, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016;4(10):781–796. doi:10.1016/S2213-2600(16)30265-X
   PubMed Web of Science ®Google Scholar
• Boulet LP, Gauvreau G, Boulay ME, O’Byrne P, Cockcroft DW. Clinical Investigative Collaboration CNoCoEA. The allergen bronchoprovocation model: an important tool for the investigation of new asthma anti-inflammatory therapies. Allergy. 2007;62(10):1101–1110. doi:10.1111/j.1398-9995.2007.01499.x
   PubMedGoogle Scholar
• Davis BE, Illamperuma C, Gauvreau GM, et al. Single-dose desloratadine and montelukast and allergen-induced late airway responses. Eur Respir J. 2009;33(6):1302–1308. doi:10.1183/09031936.00169008
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Lee JM, Watson RM, Irani AM, Schwartz LB, O’Byrne PM. Increased numbers of both airway basophils and mast cells in sputum after allergen inhalation challenge of atopic asthmatics. Am J Respir Crit Care Med. 2000;161(5):1473–1478. doi:10.1164/ajrccm.161.5.9908090
   PubMed Web of Science ®Google Scholar
• Parameswaran K, Liang H, Fanat A, Watson R, Snider DP, O’Byrne PM. Role for cysteinyl leukotrienes in allergen-induced change in circulating dendritic cell number in asthma. J Allergy Clin Immunol. 2004;114(1):73–79. doi:10.1016/j.jaci.2004.03.054
   PubMed Web of Science ®Google Scholar
• Holgate S, Smith N, Massanari M, Jimenez P. Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy. 2009;64(12):1728–1736. doi:10.1111/j.1398-9995.2009.02201.x
   PubMed Web of Science ®Google Scholar
• Brusselle GG, Koppelman GH. Biologic therapies for severe asthma. N Engl J Med. 2022;386(2):157–171. doi:10.1056/NEJMra2032506
   PubMed Web of Science ®Google Scholar
• Agache I, Antolin-Amerigo D, de Blay F, et al. EAACI position paper on the clinical use of the bronchial allergen challenge: unmet needs and research priorities. Allergy. 2022;77(6):1667–1684. doi:10.1111/all.15203
   PubMed Web of Science ®Google Scholar
• Haahtela T, Järvinen M, Kava T, et al. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med. 1991;325(6):388–392. doi:10.1056/NEJM199108083250603
   PubMed Web of Science ®Google Scholar
• Szefler S, Weiss S, Tonascia J, et al. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med. 2000;343(15):1054–1063.
   PubMed Web of Science ®Google Scholar